ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

ARS Pharmaceuticals reported Q1 2026 total revenue of $22.7 million, with neffy (epinephrine nasal spray) generating $17.5 million in U.S. net product revenue. The company expanded its sales force to 148 representatives, secured approval from Health Canada, and achieved European Commission marketing authorization for EURneffy 1 mg. CVS Caremark formulary approval is in final stages with expected July 2026 effective date. The Phase 2b CSU trial interim population is fully enrolled with Q4 2026 readout expected. Despite strong commercial momentum, the company reported a net loss of $60.6 million for the quarter.

05/15/2026, 6:00 AM • GlobeNewswire

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results

ARS Pharmaceuticals (Nasdaq: SPRY) announced a conference call scheduled for May 15, 2026, to discuss its first quarter 2026 financial results and business highlights. The company continues commercializing neffy®, an epinephrine nasal spray for emergency treatment of allergic reactions and anaphylaxis across multiple markets including the U.S., EU, and China.

05/07/2026, 8:00 AM • GlobeNewswire

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

ARS Pharmaceuticals reported $32.5 million in revenue for Q3 2025, primarily from neffy epinephrine nasal spray sales. The company continues to expand market presence through direct-to-consumer campaigns and has strong cash reserves of $288.2 million.

11/10/2025, 6:00 AM • GlobeNewswire

ARS Pharma Sales Jump 3,040% in Q2

ARS Pharmaceuticals reported strong Q2 2025 revenue of $15.7 million, driven by its needle-free epinephrine nasal spray neffy. Prescription volumes grew 180%, and commercial coverage reached 93%, though high operating costs led to a net loss of $44.9 million.

08/13/2025, 3:04 PM • The Motley Fool